Surface Oncology Inc

Surface Oncology — Corporate Update (November 2022)

14 slides from Surface Oncology's corporate update, Nov 2, 2022

  1. Slide 1: SRF388 Clinical Data and Business Update Call

    SRF388 Clinical Data and Business Update Call November 2, 2022 Exhibit 99.2

  2. Slide 2: Forward-looking statements

    This presentation includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended. All statements contained in this presentation other than statements of historical facts, including statements regarding future results of operations and finan

  3. Slide 3: Review of SRF388 NSCLC Data; SRF114 Advancing Towards the Clinic

    Review of SRF388 Non-Small Cell Lung Cancer Data (NSCLC) SRF114 Advancing Towards the Clinic

  4. Slide 4: Overview of SRF388: First-in-Class Antibody Targeting IL-27

    First-in-Class Antibody Targeting IL-27 High-affinity, fully human IgG1 antibody against IL-27 IL-27 is a highly immunosuppressive cytokine and serves as a “master switch” of checkpoint protein expression Translational and clinical evidence to support activity in liver and lung cancer Monotherapy ac

  5. Slide 5: IL-27 mechanism of immunosuppression

    Villarino, et al. Immunity. 2003; Saur, et al. J Immunol. 2008; Carbotti, et al. Oncotarget. 2015; Chihara, et al. Nature. 2018; DeLong, et al. Immunohorizons. 2019; Aghayev, et al. Cancer Discovery. 2022 Adaptive Immunity IFNγ IL-17 TNFα Decreased Cytokine Secretion IL-27 Macrophage or Dendritic Ce

  6. Slide 6: Gene expression analysis showing NK/CD8+ T cell activation

    PBMC Collection Gene Expression Analysis by RNA Sequencing Increased Expression of NK / CD8+ T Cell Activation Genes C1D1 pre-infusion C1D8 SRF388 Increased by SRF388 Decreased by SRF388 8 paired patient samples Granzyme A Perforin

  7. Slide 7: SRF388 clinical trial design and dose escalation safety

    Monotherapy Dose Escalation Patients with advanced solid tumors Established encouraging safety and tolerability profile up to highest dose tested (20 mg/kg) No DLTs observed to date Complementary cohorts encompassing different NSCLC disease subsets of interest: Monotherapy (up to 40 patients) contri

  8. Slide 8: Preliminary monotherapy responses in NSCLC

    Preliminary data as of 24 Aug 2022, subject to change 2 confirmed PRs in PD-L1 negative or low, squamous NSCLC and 1 durable disease stabilization in adenocarcinoma, all previously treated with PD-(L)1 antibodies 10 evaluable patients dosed with SRF388; majority at RP2D of 10 mg/kg (n=6) and above (

  9. Slide 9: IL-27 expression in tumor samples by IHC

    Stained 120 archival samples from patients with NSCLC (70 SCC, 50 adenoCa), 21 small cell lung cancer (SCLC) samples, and 20 HNSCC samples IL-27+ macrophages present in 81% of squamous NSCLC cases, 75% of adenoCa, and 95% of HNSCC Three examples of IL-27 IHC in lung SCC highlighting positive macroph

  10. Slide 10: Overview of SRF114: Antibody Targeting CCR8

    Antibody Targeting CCR8 High-affinity, fully human afucosylated IgG1 antibody against CCR8 Specifically binds and preferentially depletes CCR8+ tumor Tregs Afucosylation enhances ADCC killing Highly specific for binding CCR8 exclusively IND open Overview of SRF114

  11. Slide 11: Treg depletion with SRF114 and in vivo monotherapy activity

    Macrophage/DCs Depletion of Intra-tumoral Tregs With SRF114 Leads to In Vivo Monotherapy Activity CCR8+ Treg FcγR SRF114 SRF114 CCR8 CCR8 Macrophage/DCs NK cell FcγR Release of immuno-suppression Effector T cells Tumor cell Enhanced Anti-Tumor Response SRF114 Monotherapy Treatment Inhibits MC38 Tumo

  12. Slide 12: Pre-clinical SRF114 data support best-in-class potential

    Compelling Pre-clinical SRF114 Data Support Best In Class Potential *Comparator antibody construction based on sequences obtained from patent literature Differentiation of SRF114 SRF114 selected based on exquisite specificity to human CCR8 Constructed four comparator antibodies* and all bound human

  13. Slide 13: Anticipated Clinical Updates

    Anticipated Clinical Updates SRF388: Clinical data anticipated in H1 2023 SRF114: First patient expected soon; initial safety/efficacy clinical data in 2024

  14. Slide 14: SRF388 Clinical Data and Business Update Call

    SRF388 Clinical Data and Business Update Call November 2, 2022

Surface Oncology — Corporate Update (November 2022) on 6ix